Aktis Oncology, Inc.
- AKTS
- NASDAQ
- Biotechnology
- Targeted Radiopharmaceuticals
- Cancer Therapy (Radioconjugates)
$15.11
Today +0.33%Quote Oct 19, 2026, 08:00 PM UTC
−30.94%over the last month
Max drawdown −31.9%From 1-month high −31.7%3 months −38.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Aktis Oncology
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
79
Founded
2020
Market value
$812.1M
Quote Oct 19
Floor
$14.72
2.6% below price
Resistance
$16.03
6.1% above price
Price vs analyst targets
9 analysts
Lowest target
$35.00Highest target
$40.00
$35.00Highest target
$40.00
- Price $15.11
- Average target $37.40
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 148% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about AKTSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free